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eNTRODUCTION
Over the last decade, immune reconstitution has
merged as a general concern in hematopoietic stem
ell transplantation (HSCT). Interest in immune de-
elopment after transplantation is due to the high rate
f susceptibility to opportunistic infection and the
elationship of immune recovery to relapse of malig-
ant diseases. Infection rates for HSCT recipients
fter resolution of peritransplantation neutropenia
ave ranged from 40% to nearly 80%, depending on
he donor source and whether graft-versus-host dis-
ase (GVHD) is present [1]. Conventionally, herpes vi-
us family infections—notably, cytomegalovirus (CMV)
nd Epstein-Barr virus—have been the major oppor-
unistic viral infections that have been relevant to
ransplantation. However, community respiratory vi-
us infections, including adenovirus infections, are be-
ng increasingly described. Fungal infections are an-
ther major cause of posttransplantation morbidity
nd mortality, as well as signiﬁcant expense and mor-
idity from the prophylactic, preemptive, and thera-
eutic use of antifungal agents. Increased susceptibil-
ty to fungal infections is likely to represent defects of
oth T cell–mediated and innate immune functions in
SCT recipients. Besides the viral and fungal infec-
ions that are associated with defective cell-mediated
mmunity, late bacterial infections occur as a result of
efective antibody production, including low titers
nd defective class switching from immunoglobulin M
o immunoglobulin G. Besides infectious complica-
ions, the other evidence for the importance of post-
SCT immune reconstitution has been the decreased
fﬁcacy of hematopoietic stem cells (HSCs) for ma-
ignant disease when the graft has been manipulated
y T-cell depletion (TCD) to prevent GVHD. To
ate, the problem of delayed or defective immune
econstitution has been addressed mainly by aggres-
ive supportive care, including the prophylactic or
resumptive use of antibiotics, antifungals, and anti- b
2irals and the administration of replacement intrave-
ous immunoglobulin. In addition, innovative cellular
herapies using adoptively transferred T-cell clones or
olyclonal T-cell populations have been used experi-
entally.
The risk or severity of delayed immune reconsti-
ution may be increasing because of changes in HSCT
ractices. Use of unrelated donor or haploidentical
tem cell products increases the severity of post-
SCT immune deﬁciency as a result of the increased
isk of GVHD, as well as the use of cell-processing
ethods, eg, TCD, that remove functional T cells [2].
s will be discussed, the removal of mature T cells
rom HSC products means that one pathway for post-
ransplantation T-cell generation, the expansion of
doptively transferred T cells, is severely limited. As a
esult, generation of T lymphocytes must occur from
rethymic progenitors via a thymic-dependent path-
ay. Although difﬁcult to quantify in clinical studies,
ncreased dose intensity of both pretransplantation
onditioning and prior chemotherapy may damage the
hymic microenvironment and result in a reduced ca-
acity to support de novo T-cell development. An-
ther factor that may increase the incidence or sever-
ty of posttransplantation immune deﬁciency is the use
f HSCT in older patients who have poorer capacity
or generation of T lymphocytes than younger pa-
ients [3,4].
Functional immunity depends on cells that medi-
te both the innate and adaptive immune response.
fter HSCT, recovery of polymorphonuclear and
endritic cells is relatively rapid, occurring within
eeks. In contrast, the development of the lympho-
ytes that mediate the adaptive immune response is
ubstantially delayed and in some cases may never
ccur. The reasons for the delayed development of
unctional T and B lymphocytes, compared with my-
loid cells, are unclear. One reason for the delay may
e differences in the ontogeny of lymphoid and non-
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Immune Reconstitution
Bymphoid populations. For example, the development
f immunocompetence in the fetus occurs signiﬁ-
antly later than the development of nonlymphoid
ells. The thymic anlage is colonized with hematopoi-
tic cells at 7 to 8 weeks’ gestation, but antigen-
peciﬁc T-cell function does not develop until the
econd trimester, and a full repertoire and normal
umbers of T lymphocytes are not present until post-
atal life. Thus, if T-lymphocyte development were to
ccur after HSCT at the same rate as normal fetal
ntogeny, it might be predicted that functional num-
ers of T cells might appear 3 to 4 months after
ransplantation and that full recovery might take 6 to
2 months. Recapitulation of ontogeny can explain
ome of the delays in immune reconstitution and can
ead to therapeutic strategies based on manipulation of
ymphoid progenitors.
HYMIC-DEPENDENT AND -INDEPENDENT PATHWAYS
OR T-CELL GENERATION
Several concepts that are critical for understand-
ng posttransplantation immune deﬁciency will be dis-
ussed. It is postulated that all posttransplantation
-lymphocyte populations are derived either from (1)
rethymic cells that must differentiate in the host via
hymic-dependent pathways or (2) postthymic cells
hat can undergo expansion in the host without a
equirement for host thymic function (thymic-inde-
endent pathway) [5]. The thymic-dependent path-
ay recapitulates ontogeny in that it is slow, but it can
enerate a diverse repertoire of T lymphocytes that
re host tolerant. Critically, the thymic-dependent
athway is predicated on the generation of lymphoid
rogenitors that can trafﬁc, engraft, and develop in
he thymus. Generation of lymphocytes proceeds
hrough stages marked by different levels of commit-
ent, differentiation, proliferation, and survival. Mu-
ine experiments have demonstrated that the number
f transplanted HSCs is a critical determinant of thy-
ic recovery. Therefore, manipulations to increase
ymphoid commitment and progenitor expansion or
o transplant large numbers of committed progenitors
ay be therapeutically useful. The thymic-dependent
athway is also predicated on the thymus providing an
dequate microenvironment for the development of T
ymphocytes. The function of the thymus in a trans-
lant patient is probably never the same as that in a
ormal fetus. The thymic microenvironment is dam-
ged in HSCT recipients by age-related thymic invo-
ution, exposure to cytotoxic drugs or radiation, and
VHD. Therefore, reversal of thymic involution,
rotection of the thymus from injury, and replace-
ent of thymic functions are likely to be important in
nsuring that the thymic-dependent pathway is func-
ional. Because of the delays inherent in the thymic- e
B & M Tependent pathway, much of the T-cell function seen
arly after HSCT is occurring via the thymic-inde-
endent pathway. Homeostatic peripheral expansion
f T lymphocytes occurs in lymphopenic hosts and is
mechanism by which adoptively transferred T cells
n the graft can rapidly expand. Cells generated after
SCT by thymic-independent pathways have a nar-
ower and skewed repertoire than T lymphocytes gen-
rated de novo in the thymus. However, the ability to
ndergo rapid expansion in a thymic-independent
anner offers the potential for clinically signiﬁcant
xpansion of cells with deﬁned speciﬁcities, eg, against
athogens (CMV, Epstein-Barr virus, and adenovirus)
r tumor cells.
SC AND PROGENITOR CELL BIOLOGY
The ability to directly manipulate the earliest lym-
hoid progenitors in hematopoietic transplant grafts
ould theoretically lead to novel therapies aimed at
mproving immune reconstitution after transplanta-
ion. However, our understanding of how the early
tages of human lymphopoiesis are regulated has been
imited until recently by the lack of suitable assays for
he human system. The classic model of hematopoie-
is assumes that HSCs differentiate initially down 2
utually exclusive pathways, the ﬁrst restricted to the
yeloerythroid lineage and the second restricted to
he lymphoid lineage. Studies using adult murine bone
arrow that support this concept have identiﬁed com-
on lymphoid progenitors (CLPs), ie, progenitors
erived from HSCs that have lost myeloid potential
ut retain the ability to differentiate into all lymphoid
ell types [6]. Murine CLPs are immunophenotypi-
ally distinct from murine HSCs; the 2 populations
re distinguished most importantly by differential ex-
ression of interleukin (IL)–7 receptor  (IL-7R).
owever, more recent studies in murine bone marrow
nd thymus have identiﬁed other types of progenitor
athways that can generate lymphoid cells. For exam-
le, the early thymocyte progenitor has been identi-
ed in mouse thymus and lacks IL-7R, thus leading
o controversy over whether CLPs or other progeni-
ors are the direct precursors of the earliest thymo-
ytes.
With the development of in vitro and in vivo assay
ystems able to measure human lymphopoiesis, human
ymphoid progenitor stages and how they are regu-
ated can now be studied. The Crooks laboratory has
solated multilymphoid progenitors capable of gener-
ting at least B, natural killer, and dendritic cells from
ord blood, bone marrow, and mobilized peripheral
lood on the basis of expression of the surface antigen
D7 [7]. These progenitors express IL-7R and lym-
hoid-associated genes such as Pax5 and Tdt. How-
ver, another progenitor population can be found in
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4ord blood that lacks IL-7R expression. These
D34CD38CD7 cells represent an earlier step in
ymphoid commitment that precedes the onset of
ax5 or Tdt expression. The existence of this popu-
ation suggests that lymphoid commitment in the hu-
an is not dependent on IL-7R expression. The
xistence of analogous IL-7R–negative lymphoid
rogenitors in the human bone marrow has not yet
een reported. However, CD34CD38CD7 cells
re found at high frequency in the bone marrow from
atients with severe combined immune deﬁciency
aused by a mutation in the signaling component of
he IL-7R (ie, common  or c gene deﬁciency). This
upports the notion that IL-7R signaling is not re-
uired for the earliest stages of human lymphoid dif-
erentiation.
By using the in vitro assays and immunopheno-
ypes developed for cord blood and bone marrow, the
rooks laboratory has begun to characterize distinct
rogenitor subpopulations in the human thymus.
D7 cells make up the bulk of the CD34 progen-
tor population in the thymus and possess both T-cell
nd natural killer cell potential. More primitive pro-
enitors with lymphomyeloid lineage potential can
lso be identiﬁed in the human thymus at very low
requency.
Cotransplantation of CLPs with puriﬁed HSCs
as been shown to be effective at protection form
nfection in a model of murine CMV infection [8]. It
s important to note that CLPs, which have not yet
ndergone selection in the thymus, do not cause
VHD in allogeneic models of bone marrow trans-
lantation. One of the major obstacles to the clinical
se of CLPs to enhance lymphopoiesis after trans-
lantation is their rarity and relatively poor engraft-
ent and proliferation potential. Novel strategies to
vercome these biological limitations are under explo-
ation.
HYMIC MICROENVIRONMENTAL FUNCTION
ND HSCT
Besides the model of recapitulation of ontogeny, a
econd explanation for the delayed lymphocyte recov-
ry in HSCT recipients is damage to the thymic
icroenvironment. The thymus consists of HSC-
erived thymocytes that are developing into T lym-
hocytes, as well as diverse populations of resident
icroenvironmental cells, most of which are not he-
atopoietically derived. The thymocytes, although
ransient, are the vast majority (99%) of the cells in
normal thymus. Classic models of thymopoiesis have
mphasized the positive and negative signals provided by
he microenvironmental cells for the developing thymo-
ytes. The clonotypic T-cell receptor (TCR) for antigen
s generated by the process of V(D)J recombination o
4ccurring in the most immature CD3CD4CD8
triple-negative) thymocytes. Thymocytes with differ-
nt TCR speciﬁcities are positively and negatively
elected at subsequent CD3CD4CD8 (double-
ositive) and CD3CD4 or CD3CD8 (single-
ositive) stages of differentiation. Because of the large
mount of culling of cells that occurs via negative
election, the maintenance of a pool of thymocytes
hroughout life requires a continuous stream of newly
roduced triple-negative cells. The expansion of tri-
le-negative cells is mediated in the mouse by IL-7
nd Kit ligand signals. The role of IL-7 in human
hymocyte development has been established in severe
ombined immune deﬁciency syndromes caused by IL-
R or c deﬁciencies, but the role of Kit signaling is
ot well established for humans. IL-7 and Kit ligand
re both produced by subsets of thymic epithelial cells
TECs), which can be classiﬁed on the basis of ana-
omic location (cortical versus medullary), gene ex-
ression, and function. In a revision of classic uni-
irectional models of interactions between the
icroenvironment and thymocytes, there is evidence
hat TEC development and maintenance are recipro-
ally dependent on signals derived from developing
hymocytes. An example of these reciprocal interac-
ions is the production of ﬁbroblast growth factors
FGFs) by thymocytes that interact with an epithelial-
peciﬁc FGF receptor (FGFR2-IIIb) expressed by the
ECs.
Multiple mechanisms for damage to the thymic
icroenvironment may be operative in HSCT recip-
ents. In the 1970s, it was noted that in animals with
xperimental GVHD, the alloreactive cells inﬁltrated
he thymus and caused inﬂammation. Subsequent
tudies have shown that TECs are a target of this
llogeneic response. Although an effect of posttrans-
lantation immune suppressive drugs, particularly
lucocorticoids, might intuitively be expected to sup-
ress thymopoiesis by killing thymocytes, such effects
ave been shown only in animal models, but not in
linical studies of patients receiving prophylactic im-
unosuppression who did not develop GVHD [3,9].
hus, GVHD itself is likely to be more inhibitory of
hymopoiesis than the drugs used to prevent GVHD.
ther studies have shown that TECs are decreased in
umber by aging and are killed by cytotoxic agents,
uch as radiation therapy and alkylating agents, that
re used in pretransplantation conditioning. The loss
f TECs likely results in decreased intrathymic IL-7
roduction, thus decreasing the ability of the thymus
o sustain the de novo generation of T cells.
The recognition of TEC damage as a common
athway for thymic microenvironmental dysfunction
pens up many avenues for research aimed at improv-
ng immune reconstitution. Among the strategies that
re in need of translational study are the replacement
f intrathymic IL-7 production by either systemic
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Immune Reconstitution
Bdministration of IL-7 or cellular therapy and the
rotection and regeneration of TECs by administra-
ion of ligands for FGFR2-IIIb: eg, FGF-7 (keratin-
cyte growth factor) [10,11].
OMEOSTATIC PROLIFERATION IN
MMUNE RECONSTITUTION
Until the 1990s, it was generally believed that
ost T lymphocytes were not in the cell cycle but
ould be made competent for proliferation by recog-
ition of antigenic peptides by the TCR and engage-
ent of costimulatory receptors. IL-2–dependent ac-
ivation and proliferation of the stimulated T cells,
ctivated induced apoptosis, or induction of anergy of
he stimulated T cells would then result. However, it
s now clear that low-level proliferation of all T-
ymphocyte subsets occurs under normal condi-
ions, even when there is no nominal antigenic
timulation. During fetal and early postnatal life,
omeostatic cycling expands the number of mature
lymphocytes so that T-cell numbers are not to-
ally constrained by the capacity of the thymus to
roduce new cells. Later in postnatal life, homeo-
tatic cycling allows the continued maintenance of a
road repertoire of T-cell speciﬁcities and functions,
ven as the thymus involutes. Under conditions of
ymphopenia, the homeostatic proliferation of mature
lymphocytes increases, thus resulting in homeo-
tatic peripheral expansion. Homeostatic peripheral
xpansion has been demonstrated under experimental
onditions, as well as clinically in lymphopenic HSCT
nd in human immunodeﬁciency virus–infected pa-
ients, and is largely responsible for the thymic-inde-
endent reconstitution of immunity that is observed
arly after HSCT.
The regulation of homeostatic cycling and periph-
ral expansion has been elucidated for different lym-
hocyte subsets [12]. Such homeostatic cycling or pro-
iferation of naive CD4 and CD8 T lymphocytes is
nduced by interactions of the TCR with self-peptides
nd IL-7 in the periphery. In the absence of either
L-7 or major histocompatibility molecules to present
elf-peptide antigens, adoptively transferred naive T
ells will fail to survive. IL-7 levels have been shown to
e inversely related to lymphocyte number. The in-
reased levels of IL-7 observed in lymphopenic con-
itions may explain the homeostatic peripheral expan-
ion of naive T cells that is observed in lymphopenic
osts and, indeed, can be replicated in nonlym-
hopenic hosts by the administration of pharmaco-
ogic doses of IL-7. Stimulation of naive T cells via
CR and IL-7 signals may result in expansion of the
aive T-cell pool or of conversion to memory T lym-
hocytes. Memory T lymphocytes differ from naive
ells in their requirements for homeostatic cycling and h
B & M Teripheral expansion. CD4 memory T cells are
ainly dependent on IL-7 alone, but optimal prolif-
ration occurs in the presence of both IL-7 and TCR
ignals. In contrast, CD8 memory T-cell homeo-
tatic cycling or proliferation requires another c cy-
okine, IL-15—not IL-7—and does not require TCR
ignals.
The regulation of homeostasis may be more com-
lex than simply combinations of cytokine and TCR
ignals. For example, activation of human dendritic
ells by thymic stroma-derived lymphopoietin results
n their ability to support proliferation of mature T
ymphocytes that acquire a central memory phenotype
13]. The mechanism of expansion is dependent on
CR and B7 costimulation signals but, like homeo-
tatic proliferation, is not dependent on foreign anti-
ens.
The application of our knowledge of T-cell ho-
eostatic cycling or proliferation is highly relevant to
linical HSCT. The skewing of the repertoire toward
umor antigens is likely to be desirable for effective
mmunotherapy of cancer. In addition, proliferation
f cells with weak afﬁnities for antigen are magniﬁed
uring homeostatic peripheral expansion, a property
hat may be particularly useful for antitumor re-
ponses. Evidence of the ability of IL-7 treatment to
uplicate some of the conditions of lymphopenia-
ssociated homeostatic peripheral expansion suggests
hat pharmacologic IL-7 therapy may be useful in
ugmenting immune responses to tumor vaccines.
he ability of adoptively transferred antigen-speciﬁc
lymphocytes to survive and expand to clinically
elevant numbers may be augmented by IL-7 and
L-15 therapy.
In addition to the opportunities for therapy of-
ered by the understanding of the processes of homeo-
tatic cycling and peripheral expansion, there are sev-
ral pitfalls and unresolved questions that need to be
ddressed. Although IL-7 therapy is an attractive way
o address the problem of thymic microenvironmental
amage, the dual effects of IL-7 in promoting the
xpansion and differentiation of both thymocytes and
omeostatic cycling and expansion of mature T lym-
hocytes mean that studies of IL-7–mediated thymic
timulation should be viewed with caution. IL-7 is
ecessary for the survival of alloreactive T lympho-
ytes that mediate GVHD and may exacerbate
VHD in an allogeneic setting. Clinical trials of IL-7
o stimulate thymopoiesis may require either TCD of
he stem cell product in allogeneic HSCT or initial
tudy in an autologous setting. Furthermore, because
he effects of IL-7 on mature T-cell subsets seem to be
ose dependent, the optimal dose for thymic stimula-
ion may differ from that needed for stimulation of
omeostatic peripheral expansion.
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4UMMARY
Although the problem of immune reconstitution
fter HSCT has been addressed indirectly by sup-
ortive care measures, new knowledge of the biol-
gy of transplantation should allow us to move
orward in directly attacking the problem. Strate-
ies to improve the development of T lymphocytes
ia thymic-dependent pathways involve the gener-
tion, isolation, and manipulation of prethymic
ells, including CLPs. Understanding of the recip-
ocal relationships between lymphoid progenitors
nd the thymic microenvironment have allowed
mall-animal model testing of either IL-7 replace-
ent or FGF-mediated protection and regeneration
f TECs. The elucidation of the TCR and cytokine
equirements for the thymus-independent homeo-
tatic cycling and peripheral expansion of mature T
ells is leading to studies of either enhancement of
mmune responses to antigens or to improved sur-
ival and efﬁcacy of adoptively transferred T lym-
hocytes. Although all of these approaches have
olid preclinical supporting data, a major challenge
o the HSCT community will be the implementa-
ion of clinical trials that will allow proper evalua-
ion of their safety, efﬁcacy, and best use.
CKNOWLEDGMENTS
Supported by National Institutes of Health grant
os. HL77912, HL73104 (G.M.C.), AI50765, HL54729,
L70005, and HL73104 (K.W.).
EFERENCES
1. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic
bone marrow transplantations: comparison of incidence in re-
lated and unrelated donor transplant recipients. Blood. 1995;86:
3979-3986.
62. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of
immune reconstitution after unrelated and related T-cell-de-
pleted bone marrow transplantation: effect of patient age and
donor leukocyte infusions. Blood. 1999;93:467-480.
3. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting
thymic function after allogeneic hematopoietic stem cell trans-
plantation. Blood. 2001;97:1458-1466.
4. Hakim FT, Memon SA, Cepeda R, et al. Age-dependent inci-
dence, time course, and consequences of thymic renewal in
adults. J Clin Invest. 2005;115:930-939.
5. Mackall CL, Bare CV, Granger LA, et al. Thymic-independent
T cell regeneration occurs via antigen-driven expansion of
peripheral T cells resulting in a repertoire that is limited in
diversity and prone to skewing. J Immunol. 1996;156:4609-
4616.
6. Kondo M,Weissman IL, Akashi K. Identiﬁcation of clonogenic
common lymphoid progenitors in mouse bone marrow. Cell.
1997;91:661-672.
7. Hao QL, Zhu J, Price MA, et al. Identiﬁcation of a novel,
human multilymphoid progenitor in cord blood. Blood. 2001;
97:3683-3690.
8. Arber C, BitMansour A, Sparer TE, et al. Common lymphoid
progenitors rapidly engraft and protect against lethal murine
cytomegalovirus infection after hematopoietic stem cell trans-
plantation. Blood. 2003;102:421-428.
9. Kong FK, Chen CL, Cooper MD. Reversible disruption of
thymic function by steroid treatment. J Immunol. 2002;168:
6500-6505.
0. Bolotin E, Smith S, Smogorewska EM, Widmer M, Weinberg
KI. Enhancement of thymopoiesis after bone marrow trans-
plant by in vivo IL-7. Blood. 1996;88:1887-1894.
1. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection
from thymic epithelial cell injury by keratinocyte growth factor:
a new approach to improve thymic and peripheral T-cell re-
constitution after bone marrow transplantation. Blood. 2002;99:
4592-4600.
2. Guimond M, Fry TJ, Mackall CL. Cytokine signals in T-cell
homeostasis. J Immunother. 2005;28:289-294.
3. Watanabe N, Hanabuchi S, Soumelis V, et al. Human thymic
stromal lymphopoietin promotes dendritic cell-mediated CD4
T cell homeostatic expansion. Nat Immunol. 2004;5:426-434.
